A combined biomarker pattern improves the discrimination of lung cancer

Biomarkers

Volumn 16, Issue 1, 2011, Pages 20-30

  Liu, Liyun ^a,b,c   Liu, Jifu ^d   Wang, Yinping ^e   Dai, Songwei ^a,b   Wang, Xiaomin ^a,b   Wu, Shanshan ^d   Wang, Jianing ^a,b   Huang, Lingyun ^a,b   Xiao, Xueyuan ^a,b   He, Dacheng ^a,b  

^a BEIJING NORMAL UNIVERSITY   (China)

^b Universities' Confederated Institute of Proteomics   (China)

^c National Institute for Communicable Disease Control and Prevention   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

biomarker; lung cancer; SAA; SELDI; TTR

Indexed keywords

AMYLOID A PROTEIN; BIOLOGICAL MARKER; PREALBUMIN;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER STAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOPRECIPITATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADENOCARCINOMA; ADULT; AGED; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOPRECIPITATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREALBUMIN; PROTEIN ARRAY ANALYSIS; SENSITIVITY AND SPECIFICITY; SERUM AMYLOID A PROTEIN; SMALL CELL LUNG CARCINOMA; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 79251514008     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2010.521257     Document Type: Article

References (40)

1. Adam BL, Qu Y Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y Feng Z, Wright GL Jr. (2002). Serum protein fngerprinting coupled with a pat-tern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62:3609-14.
2. Altland K, Winter P. (2003). Polyacrylamide gel electrophoresis fol-lowed by sodium dodecyl sulfate gradient polyacrylamide gel electrophoresis for the study of the dimer to monomer transition of human transthyretin. Electrophoresis 24:2265-71.
3. Basu TK, Sasmal P. (1988). Plasma vitamin A, retinol-binding protein, and prealbumin in postoperative breast cancer patients. Int J Vitam Nutr Res 58:281-3.
4. Bausserman LL, Herbert PN, Rodge R, Nicolosi RJ. (1984). Rapid clear-ance of serum amyloid A from high-density lipoproteins. Biochim Biophys Acta 792:186-91.
5. Benson MD, Cohen AS. (1979). Serum amyloid A protein in amy-loidosis, rheumatic and neoplastic diseases. Arthritis Rheum 22:36-42.
6. Bergen HR, Zeldenrust SR, Butz ML, Snow DS, Dyck PJ, Dyck PJ, Klein CJ, O'Brien JF, Tibodeau SN, Muddiman DC (2004). Identifcation of transthyretin variants by sequential proteomic and genomic analysis. Clin Chem 50:1544-52.
7. Chen G, Gharib TG, Wang H, Huang CC, Kuick R, Tomas DG, Shedden KA, Misek DE, Taylor JM, Giordano TJ, Kardia SL, Iannettoni MD, Yee J, Hogg PJ, Orringer MB, Hanash SM, Beer DG. (2003). Protein profles associated with survival in lung ade-nocarcinoma. Proc Natl Acad Sci USA 100:13537-42.
8. Chen YD, Zheng S, Yu JK, Hu X. (2004). Artifcial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin Cancer Res 10:8380-5.
9. Cho WC, Yip TT, Yip C, Yip C, Yip V, Thulasiraman V, Ngan RK, Yip TT, Lau WH, Au JS, Law SC, Cheng WW, Ma VW, Lim CK. (2004). Identification of serum amyloid A protein as a poten-tial useful biomarkers to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clinical Cancer Research 10:43-52.
10. d'Eril GM, Anesi A, Maggiore M, Leoni V. (2001). Biological variation of serum amyloid A in healthy subjects. Clin Chem 47:1498-9.
11. Ellegård LH, Bosaeus IG (2008). Biochemical indices to evaluate nutri-tional support for malignant disease. Clin Chim Acta 390:23-7.
12. Fung ET, Yip TT, Lomas L, Wang Z, Yip C, Meng XY, Lin S, Zhang F, Zhang Z, Chan DW, Weinberger SR. (2005). Classifcation of can-cer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 115:783-9.
13. Gericke B, Raila J, Sehouli J, Haebel S, Könsgen D, Mustea A, Schweigert FJ. (2005). Microheterogeneity of transthyretin in serum and ascitic fuid of ovarian cancer patients. BMC Cancer 5:133.
14. Glojnaric I, Casl MT, Simic D, Lukac J. (2001). Serum amyloid A protein (SAA) in colorectal carcinoma. Clin Chem Lab Med 39:129-33.
15. Granville CA, Dennis PA. (2005). An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 32:169-76.
16. Howard BA, Wang MZ, Campa MJ, Corro C, Fitzgerald MC, Patz EF Jr. (2003). Identifcation and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorp-tion/ionization-time of fight spectra analysis. Proteomics 3: 1720-4.
17. Ihara H, Matsumoto T, Shino Y Hashizume N, Takase M, Nagao J, Sumiyama Y (2003). Selective use of transthyretin and retinol-binding protein as markers in the postoperative assessment of protein nutritional status. J Clin Lab Anal 17:1-5.
18. Imanishi T. (1981). Clinical and experimental studies on the profles of serum proteins in acute hepatic injury. Gastroenterol Jpn 16:493-505.
19. Kaneti J, Winikof Y Zimlichman S, Shainkin-Kestenbaum R. (1984). Importance of serum amyloid A (SAA) level in monitoring dis-ease activity and response to therapy in patients with prostate cancer. Urol Res 12:239-41.
20. Kiernan UA, Tubbs KA, Nedelkov D, Niederkofer EE, Nelson RW. (2003). Detection of novel truncated forms of human serum amy-loid A protein in human plasma. FEBS Lett 537:166-70.
21. Kimura M, Tomita Y Imai T, Saito T, Katagiri A, Ohara-Mikami Y Matsudo T, Takahashi K. (2001). Signifcance of serum amyloid A on the prognosis in patients with renal cell carcinoma. Cancer (Phila.) 92:2072-5.
22. Lim A, Prokaeva T, McComb ME, Connors LH, Skinner M, Costello CE. (2003a). Identifcation of S-sulfonation and S-thiolation of a novel transthyretin Phe33Cys variant from a patient diag-nosed with familial transthyretin amyloidosis. Protein Sci 12: 1775-85.
23. Lim A, Sengupta S, McComb ME, Téberge R, Wilson WG, Costello CE, Jacobsen DW. (2003b). In vitro and in vivo interactions of homocysteine with human plasma transthyretin. J Biol Chem 278:49707-13.
24. Liu D, Wang X, Zhang L, Dai SW, Liu L, Liu J, Wu S, Yang S, Fu S, Xiao X, He D. (2007a). Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer. Biomed Environ Sci 20:33-40.
25. Liu L, Liu J, Dai S, Wang X, Wu S, Wang J, Huang L, Xiao X, He D. (2007b). Reduced transthyretin expression in sera of lung cancer. Cancer Sci 98:1617-24.
26. Liu L, Wang J, Liu B, Dai S, Wang X, Chen J, Huang L, Xiao X, He D. (2008). Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma. J Cell Biochem 104:745-55.
27. Malle E, De Beer FC (1996). Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 26:427-35.
28. Marten NW, Sladek FM, Straus DS. (1996). Efect of dietary protein restriction on liver transcription factors. Biochem J 317:361-70.
29. Mountain CF. (1997). Revisions in the international system for staging lung cancer. Chest 111:1710-17.
30. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. (2002). Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572-7.
31. Poon TC (2007). Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev Proteomics 4:51-65.
32. Raynes JG, Eagling S, McAdam KP. (1991). Acute-phase protein synthesis in human hepatoma cells. Diferential regulation of serum amyloid A (SAA) and haptoglobin by interleukin-1 and interleukin-6. Clin Exp Immunol 83:488-491.
33. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. (1999). Reference distributions for the negative acutephase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. Clin Lab Anal 13:273-9.
34. Schweigert FJ, Wirth K, Raila J. (2004). Characterization of the microheterogeneity of transthyretin in plasma and urine using SELDI-TOF-MS immunoassay. Proteome Sci 2:5.
35. Ward DG, Cheng Y, N'Kontchou G, Tar TT, Barget N, Wei W, Billingham LJ, Martin A, Beaugrand M, Johnson PJ. (2006a). Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br J Cancer 94:287-92.
36. Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, Wakelam MJ, Johnson PJ, Martin A. (2006b). Identifcation of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 94:1898-905.
37. Xiao T, Ying W, Li L, Hu Z, Ma Y, Jiao L, Ma J, Cai Y, Lin D, Guo S, Han N, Di X, Li M, Zhang D, Su K, Yuan J, Zheng H, Gao M, He J, Shi S, Li W, Xu N, Zhang H, Liu Y, Zhang K, Gao Y, Qian X, Cheng S. (2005). An approach to studying lung cancer-related proteins in human blood. Mol Cell Proteomics 4:1480-6.
38. Xiao X, Liu D, Tang Y, Guo F, Xia L, Liu J, He D. (2004). Development of proteomic patterns for detecting lung cancer. Dis Markers 19:33-9.
39. Yamada T. (1999). Serum amyloid A (SAA): a concise review of biol-ogy, assay methods and clinical usefulness. Clin Chem Lab Med 37:381-8.
40. Yu Y, Chen S, Wang LS, Chen WL, Guo WJ, Yan H, Zhang WH, Peng CH, Zhang SD, Li HW, Chen GQ. (2005). Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser des-orption/ionization-based decision tree classifcation. Oncology 68:79-86.